Question

In: Biology

testing a series of pharmaceutical agents for their effects on the motor system. In the initial...

testing a series of pharmaceutical agents for their effects on

the motor system. In the initial state of the system, electrically

stimulating the nerve cell will generate a muscle contraction in

proportion to the intensity of the stimulation.

When tested by stimulating the nerve, the muscle again contracts with normal force and duration.

Agent X is then added to the preparation and this time, electrically stimulating the

nerve fails to elicit any muscle contraction. Direct stimulation of the muscle, elicits normal contraction.

Q)Assuming Agent X alters ion conductances.

Nicotine, an acetylcholine agonist, is added to the preparation. Would

the response of the muscle in the presence of both nicotine and Agent

X be different or the same as the response in the presence of nicotine

alone? Justify your answer.

however, elicits normal contraction.

Solutions

Expert Solution

There two key things to remember:

  1. Agent X seems to inhibit neurons' capability of transmitting action potentials by interrupting one type of element (ion channels) of the cycle (enter of Ca2+ > enter of Na+ > getaway of K+) from the cell.
  2. The response of the muscle in presence of nicotine is a prolonged contraction, since the nicotinic acetylcholine receptors (nAChR) have more affinity for this ligand than for acetylcholine, these receptors are the 1st step in the action potential cycle (they're involved in the entering of Ca2+ to cell through nAChR since these are ligand-gated ion channels).

Therefore, the response of the muscle in presence of Agent X and Nicotine is: different than in "nicotine only" assay, but, there are 2 types of different:

  1. Assuming Agent X affects negatively the entering of Ca2+ ions to cell: the muscle would only contract when stimulated electrically.
  2. Assuming Agent X affects negatively the entering/exiting of Na+/K+ ions to cell: the muscle wouldn't contract since there won't be occurring action potentials than can stimulate the motor neurons.

Related Solutions

Klyne Corporation manufactures pharmaceutical products that are sold through a network of sales agents. The agents...
Klyne Corporation manufactures pharmaceutical products that are sold through a network of sales agents. The agents are paid a commission of 24% of sales. The income statement for the year ending December 31, 2017, is as follows: KLYNE CORPORATION Income Statement For the Year Ending December 31, 2017   Sales $ 29,000,000   Cost of goods sold      Variable $ 14,790,000         Fixed 2,876,000    17,666,000   Gross margin 11,334,000   Selling and marketing expenses      Commissions 6,960,000         Fixed costs 3,270,000    10,230,000   Operating income...
Klyne Corporation manufactures pharmaceutical products that are sold through a network of sales agents. The agents...
Klyne Corporation manufactures pharmaceutical products that are sold through a network of sales agents. The agents are paid a commission of 24% of sales. The income statement for the year ending December 31, 2017, is as follows: KLYNE CORPORATION Income Statement For the Year Ending December 31, 2017   Sales $ 29,000,000   Cost of goods sold      Variable $ 14,790,000         Fixed 2,876,000    17,666,000   Gross margin 11,334,000   Selling and marketing expenses      Commissions 6,960,000         Fixed costs 3,270,000    10,230,000   Operating income...
In the autonomous motor system there is a 2-step connection (i.e., 2 neurons in series) from...
In the autonomous motor system there is a 2-step connection (i.e., 2 neurons in series) from the brain to the target muscles. This is different from the somatic motor system (only 1 neuron). Please list and briefly explain which advantage(s) in control this 2-step process provides.
What are the main ways of delivering pharmaceutical agents into the body? Describe one of these...
What are the main ways of delivering pharmaceutical agents into the body? Describe one of these routes in more detail.
Should the Addictions be Treated with Pharmaceutical Agents? Although he is a physician, Breggin (2008) has...
Should the Addictions be Treated with Pharmaceutical Agents? Although he is a physician, Breggin (2008) has long been a critic of the pharmaceutical industry. For example, he observed that “Drug companies heavily promote the unproven speculation that the problems they treat are biological in origin and result from biochemical imbalances.” This is, as he points out, an unproven hypothesis. It appears to be right, but sometimes the accepted theory is proven to be absolutely wrong. For example, 50 years ago...
Lionel Corporation manufactures pharmaceutical products sold through a network of sales agents in the United States...
Lionel Corporation manufactures pharmaceutical products sold through a network of sales agents in the United States and Canada. The agents are currently paid an 18% commission on sales; that percentage was used when Lionel prepared the following budgeted income statement for the fiscal year ending June 30, 2019: Lionel Corporation Budgeted Income Statement For the Year Ending June 30, 2019 ($000 omitted) Sales $ 28,500 Cost of goods sold Variable $ 12,825 Fixed 3,500 16,325 Gross profit $ 12,175 Selling...
Lionel Corporation manufactures pharmaceutical products sold through a network of sales agents in the United States...
Lionel Corporation manufactures pharmaceutical products sold through a network of sales agents in the United States and Canada. The agents are currently paid an 18% commission on sales; that percentage was used when Lionel prepared the following budgeted income statement for the fiscal year ending June 30, 2019: Lionel Corporation Budgeted Income Statement For the Year Ending June 30, 2019 ($000 omitted) Sales $ 30,100 Cost of goods sold Variable $ 13,545 Fixed 3,612 17,157 Gross profit $ 12,943 Selling...
Lionel Corporation manufactures pharmaceutical products sold through a network of sales agents in the United States...
Lionel Corporation manufactures pharmaceutical products sold through a network of sales agents in the United States and Canada. The agents are currently paid an 18% commission on sales; that percentage was used when Lionel prepared the following budgeted income statement for the fiscal year ending June 30, 2019: Lionel Corporation Budgeted Income Statement For the Year Ending June 30, 2019 ($000 omitted) Sales $ 30,200 Cost of goods sold Variable $ 13,590 Fixed 3,624 17,214 Gross profit $ 12,986 Selling...
Lionel Corporation manufactures pharmaceutical products sold through a network of sales agents in the United States...
Lionel Corporation manufactures pharmaceutical products sold through a network of sales agents in the United States and Canada. The agents are currently paid an 18% commission on sales; that percentage was used when Lionel prepared the following budgeted income statement for the fiscal year ending June 30, 2019: Lionel Corporation Budgeted Income Statement For the Year Ending June 30, 2019 ($000 omitted) Sales $ 30,200 Cost of goods sold Variable $ 13,590 Fixed 3,624 17,214 Gross profit $ 12,986 Selling...
Lionel Corporation manufactures pharmaceutical products sold through a network of sales agents in the United States...
Lionel Corporation manufactures pharmaceutical products sold through a network of sales agents in the United States and Canada. The agents are currently paid an 18% commission on sales; that percentage was used when Lionel prepared the following budgeted income statement for the fiscal year ending June 30, 2019 Lionel Corporation Budgeted Income Statement For the Year Ending June 30, 2019 ($000 omitted) Sales $ 29,000 Cost of goods sold Variable $ 13,050 Fixed 3,480 16,530 Gross profit $ 12,470 Selling...
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT